Daily Stock List
N-Viro International Corp. (NVIC)
StockOodles and OTC Stock Review reported previously on N-Viro International Corp. (NVIC), and today we report on the Company, here at the QualityStocks Daily Newsletter.
N-Viro International Corp. is a leader in the conversion of organic materials generated from industrial, agricultural, and municipal sources. The Company integrates advanced technology with 21st-century design for successful commercial application of its alternative energy product called N-Viro Fuel™. N-Viro combines its proprietary, patented technologies, unique services, and materials handling expertise to provide turnkey solutions in soil enrichment and alternative fuel development. N-Viro International’s sister company is N-Viro Energy Limited. N-Viro International is based in Toledo, Ohio and the Company lists on the OTCQB.
The N-Viro patented technology involves mixing a bioorganic material with alkaline reagents, which prepares the bioorganic for a chemical conversion. The production of N-Viro Fuel™ is from bioorganic waste. It provides coal-fired power plants a renewable energy product. Additionally, N-Viro Fuel™ is easily mixed with coal; is a Btu biomass-derived fuel; and equipment retrofits are minimal. It uses the selective and pre-tested fly ash as an alkaline additive. It can use waste heat from the power plant to the fuel system.
N-Viro also has its N-Viro Soil™ - a lime substitute. It’s used as a soil amendment, lime substitute, landfill cover, and land reclamation in the United States, the United Kingdom, Israel, Australia, and Canada. N-Viro Soil™ improves texture and water-holding capacity in soil to promote root growth.
Pertaining to Alternative Energy, the N-Viro Fuel™ Energy System interacts with coal-fired power plants. Coal fired power plants burning high sulfur coal inject limestone for SOx removal. The N-Viro Fuel™ energy system recycles the by-product containing substantial lime to the process. Operationally, the N-Viro Fuel™ energy system efficiently consumes waste heat, and lime. N-Viro Fuel™ creates ammonia for NOx removal. This is a savings to the Utility. N-Viro Fuel™ is an emission control strategy; liberated ammonia helps in NOx removal.
N-Viro International provided an update in October 2016 for the Jiaxing China project development. The proposed heads of terms agreement will permit the project to be executed in two phases. The expectation is that Phase I will quickly deploy the N-Viro Fuel technology to process 500 metric tons of wastewater biosolids daily into a fuel product to be used in combustion power generation. Also, the expectation is that Phase II will commence straightaway after and use the N-Viro Fuel with a gasification process for captive utility generation and grid connection.
In January 2017, N-Viro International reported that on December 21, 2016, Mr. Gene K. Richard, a member of N-Viro International's Board of Directors, submitted his resignation to the Board effective immediately and ceased to be a Director of the Company. His resignation was not the result of any dispute or disagreement with N-Viro International. Dr. Richard was a Class II director and was the Chairman of the Compensation Committee and also a member of the Nominating Committee. Dr. Richard had served as a Director since April 2014. After this resignation, the Board consists of four Directors - two Class I and two Class II Directors.
N-Viro International Corp. (NVIC), closed Wednesday's trading session at $0.0314, up 46.05%, on 1,515,138 volume with 94 trades. The average volume for the last 60 days is 245,674 and the stock's 52-week low/high is $0.0095/$1.60.
Integrated Environmental Technologies Ltd. (IEVM)
Marketbeat, Momentum Traders, HotStockChat, SmallCapVoice, Stock Guru, and OTC Picks reported previously on Integrated Environmental Technologies Ltd. (IEVM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Integrated Environmental Technologies Ltd. operates by way of its wholly-owned operating subsidiary, I.E.T., Inc. I.E.T is a manufacturing company that designs and builds equipment that incorporates unique technologies focusing on the enhancement of the environment and the health, safety, and wellbeing of present and future generations. I.E.T. produces products that have been tested, proven, and accepted by private, state, and federal agencies. All of Integrated Environmental Technologies’ products and services market and sell under the umbrella brand name, EcoTreatments™. The Company is headquartered in Little River, South Carolina.
Integrated Environmental Technologies has identified the oil and gas market as a market of major potential. Regarding healthcare, the Company reported that a second significant market lies in the disinfection of hospitals, nursing homes, and clinics. It has established a production facility in Artesia, New Mexico. Its I.E.T. subsidiary has approval by the US Food and Drug Administration (FDA) for applications of the Company’s proprietary extraction technology being introduced into the healthcare, medical, nutraceutical, and pharmaceutical markets.
I.E.T. sells anolyte disinfecting solution under the EcaFlo™ and Excelyte® brand names. The EcaFlo™ Division designs, manufactures, markets, sells, and installs proprietary Electro-Chemical Activation (ECA) equipment in the U.S.A. and globally. The innovative design of EcaFlo™ equipment is to produce EcaFlo™ Anolyte and Catholyte solutions with predictable and carefully controlled properties. The EcaFlo™ equipment utilizes an electrolytic process called electrochemical activation to reliably produce environmentally responsible solutions for cleaning, sanitizing, and disinfecting.
EcaFlo™ Anolyte and Excelyte® solutions are Environmental Protection Agency (EPA)-registered hard surface disinfectants and sanitizers. They have approvals for hospital-level use and for use as a biocide in oil and gas drilling. EcaFlo™ equipment uses a proprietary operating system.
The Company also sells a cleaning solution under the Catholyte Zero™ brand name. Catholyte Zero™ solutions are an environmentally friendly cleanser and degreaser for janitorial, sanitation, and food processing uses. Integrated Environmental Technologies received approval from the EPA to market a new Excelyte™ product named Excelyte VET that can be used to prevent Canine distemper.
Integrated Environmental Technologies has developed a new proprietary well treatment protocol. This protocol increases oil production and significantly reduces hydrogen sulfide (HsS), iron sulfide scales (FeS), bacteria, as well as bacterial deposits present in oil wells. The protocol consists of a dual treatment regimen, which uses the Company's proprietary Excelyte® and Catholyte Zero™ solutions.
Most recent reported financials for Integrated Environmental Technologies include its financial results for the three and nine month periods ended September 30, 2016. Q3 and nine-month revenue was $56,000 and $170,000, respectively. This represents a decrease from the prior year periods as the Company slowly regains momentum following the adverse impact from the quick drop in oil prices from October 2015 through January 2016, which caused oil drillers to scale down operations.
Moreover, during Q3 of 2016, the loss from operations, adjusted for non-cash expenses, averaged about $125,000 per month. This is down from roughly $195,000 per month during the same period of the prior year.
Integrated Environmental Technologies Ltd. (IEVM), closed Wednesday's trading session at $0.0032, up 6.67%, on 203,000 volume with 4 trades. The average volume for the last 60 days is 1,388,725 and the stock's 52-week low/high is $0.002/$0.03.
AdvanSource Biomaterials Corp. (ASNB)
Money Morning, S.A. Advisory, TopPennyStockMovers, Zacks, and Nebula Stocks reported earlier on AdvanSource Biomaterials Corp. (ASNB), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
AdvanSource Biomaterials Corp. is an ISO certified materials technology company. Specialists in polyurethane technologies, AdvanSource provides a variety of material formats for use in long and short term implants, as well as disposable products. Fundamentally, the Company is a foremost developer of advanced polymer materials for a wide spectrum of medical devices. AdvanSource Biomaterials has its corporate headquarters in Wilmington, Massachusetts.
AdvanSource’s business model takes advantage of its proprietary materials science technology and manufacturing expertise to expand its product sales and royalty and license fee income. The Company’s biomaterials are used in devices designed for treating a wide variety of anatomical sites and disease states. Its products include ChronoFlex AL; ChronoFlex AR; ChronoFlex C; ChronoPrene; ChronoSil; ChronoThane P; ChronoThane T; HydroMed; HydroThane; and PolyBlend.
AdvanSource’s technology has undergone development to overcome a wide assortment of design and functional challenges, from the need for dimensional stability, ease of manufacturability and demanding physical properties to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion. The Company’s new product extensions enable it to customize its proprietary polymers for specific customer applications in a wide array of device categories. Furthermore, it manufactures specialty hydrophilic polyurethanes that chiefly sell to customers as part of exclusive arrangements.
The Company’s ChronoFlex AL is a family of biodurable aliphatic polycarbonate-based thermoplastic urethanes. The design of these is to overcome surface degradation such as stress-induced microfissures. Its HydroMed is a series of ether-based hydrophilic urethanes with first rate adhesive and cohesive properties.
AdvanSource’s PolyBlend is a family of exceptionally soft, aromatic polyurethane elastomeric alloys. These can be utilized as a substitute for natural rubber or latex in numerous applications. Concerning services, in addition to customized solvent packages, the design of the Company’s coating capabilities is to help with a customer’s prototype development via multi-step dip/spray coating processes for small volumes.
Recently, AdvanSource Biomaterials announced a strategic alliance with Medibrane, Ltd. The Strategic Alliance provides for technology collaboration, development, and commercialization of medical coatings using AdvanSource’s material technologies in collaboration with Medibrane’s coating and surface modification technologies and enhancements. Medibrane is a foremost Israeli coating technology enterprise.
AdvanSource Biomaterials Corp. (ASNB), closed Wednesday's trading session at $0.04504, down 9.92%, on 3,366 volume with 2 trades. The average volume for the last 60 days is 24,531 and the stock's 52-week low/high is $0.036/$0.2049.
Bullfrog Gold Corp. (BFGC)
TopPennyStockMovers, InvestorTrendz, Wall Street Mover, PennyStocks24, Pumps and Dumps, and PennyStockLocks reported previously on Bullfrog Gold Corp. (BFGC), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
A junior exploration enterprise, Bullfrog Gold Corp. is a mineral exploration company. It has a strong asset portfolio with large prospective gold exploration projects positioned in productive mining districts within the Southwestern United States. The Company mainly explores for gold, silver, and other metals. Bullfrog Gold is headquartered in Grand Junction, Colorado. The Company lists on the OTC Markets Group’s OTCQB.
Bullfrog Gold has its Bullfrog Project. The Bullfrog Project is roughly three miles northwest of the town of Beatty and 116 miles northwest of Las Vegas, Nevada. The Bullfrog Gold Project is positioned in the prolific Walker Trend. Barrick Gold Corp. produced 2.1 million ounces of gold during the 1990’s from the primary Bullfrog open pit, the northern one third of which is now controlled by Bullfrog Gold.
In addition, Bullfrog Gold's lands include the entire Montgomery-Shoshone (M-S) deposit, from which Barrick produced an additional 220,000 ounces of gold. Also, the M-S area produced 70,000 ounces averaging 0.47 gold ounce per ton from underground mining operations in the early 1900's.
Bullfrog Gold executed an option in October 2014 to purchase 12 strategic patented claims positioned contiguous to its lands and that include the north-east half of the M-S open pit mine. The Company exercised a lease/option in March of 2015 to purchase 6 patented claims, 20 unpatented claims, and 8 mill site claims from Barrick Bullfrog, Inc.
Bullfrog Gold announced in April 2016 that mineral inventories remaining around the Montgomery-Shoshone (M-S) and Bullfrog mines have been estimated by the Company at 470,000 ounces of gold. Based on cross sectional estimation methods using a nominal gold cut-off grade of 0.3 g/t.
Average waste to mineral ratio was estimated at less than 5 to 1. The estimates are supported by close-spaced drill holes upon which Barrick Bullfrog, Inc. produced 2.3 million ounces of gold from proven and probable ore reserves during 1989 to 1999.
Last month, Bullfrog Gold announced that it completed an extensive study of comprehensive metallurgical tests. The Company announced results that apply directly to the remaining mineralization around the Montgomery-Shoshone (M-S) and Bullfrog open pit mines.
In addition, Bullfrog is scanning Barrick Bullfrog, Inc.'s paper drill hole files, which include assay certificates and other information needed to support Canadian 43-101 compliant resource estimates and open pit expansion plans. The M-S and Bullfrog deposits are amenable to heap leaching. They can support a mine cut-off grade of 0.2 g/t for leaching at coarse ROM sizes.
Bullfrog Gold Corp. (BFGC), closed Wednesday's trading session at $0.0875, up 9.99%, on 7,583 volume with 3 trades. The average volume for the last 60 days is 77,301 and the stock's 52-week low/high is $0.018/$0.19.
Pharma-Bio Serv, Inc. (PBSV)
Zacks reported previously on Pharma-Bio Serv, Inc. (PBSV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. Its core business is Food and Drug Administration (FDA) and other global regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico.
Pharma-Bio Serv has its corporate office in Dorado, Puerto Rico. Additionally, the Company has operations in the United States, Ireland, and Spain. The Company’s shares trade on the OTC Markets Group’s OTCQB.
Pharma-Bio Serv’s international team includes foremost engineering and life science professionals, quality assurance managers, and directors. Also, Pharma-Bio Serv’s services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.
Pharma-Bio Serv supports its clients throughout the product lifecycle. This includes R&D Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. In addition, this includes Quality Systems; Technology Transfer; Validation, and Manufacturing Controls & Process Support.
Recently, Pharma-Bio Serv announced that Net Revenues for the year ended October 31, 2016 were $19.5 million. This represents a drop of roughly $3.8 million, or 16 percent, versus the prior year. For the year ended October 31, 2016, the Company reported a Net Loss of roughly $0.3 million. This represents a decline in earnings of $1.9 million versus the same period the year prior.
Mr. Victor Sanchez, Pharma-Bio Serv Chief Executive Officer, said, "Throughout 2016, we have continued our strategic re-alignment and investment in resources and infrastructure designed to achieve profitability on our non-performing operations, over the long term. We have focused on consulting business development in existing and new markets, expansion of our Puerto Rico Lab facilities, development of a new Lab facility in Spain, and enhancing our Calibrations division facility in Puerto Rico."
Pharma-Bio Serv’s divisions include Scienza Labs, the abovementioned PharmaServ Academy, and Metrologix. Scienza Labs offers microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.
Pharma-Bio Serv, Inc. (PBSV), closed Wednesday's trading session at $0.83, up 16.90%, on 1,003 volume with 2 trades. The average volume for the last 60 days is 1,221 and the stock's 52-week low/high is $0.55/$1.02.
ORHub, Inc. (ORHB)
The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.74, up 1.37%, on 135,509 volume with 90 trades. The stock’s average daily volume over the past 60 days is 56,124 and its 52-week low/high is $0.05/$2.09.
NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ORHub, Inc., an NNW client providing its cloud-based health care software-as-a-service (SaaS) to decrease costs and improve outcomes in surgical care.
To view the full publication visit: http://nnw.fm/health-care-it-big-data-analytics
ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.
The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.
Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.
Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.
In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.
ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.
The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.
ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.
Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer
ORHub, Inc. Blog
ORHub, Inc. News:
NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry
NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)
ORhub, Inc. (ORHB) Engages NetworkNewsWire for Corporate Communications Solutions
TapImmune, Inc. (NASDAQ: TPIV)
The QualityStocks Daily Newsletter would like to spotlight TapImmune, Inc. (TPIV). Today, TapImmune, Inc. closed trading at $4.92, up 2.29%, on 92,255 volume with 355 trades. The stock’s average daily volume over the past 60 days is 39,573, and its 52-week low/high is $3.32/$9.828.
TapImmune, Inc. (TPIV) is leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms. By fully leveraging the scope of its technology and through collaborative partnerships and license agreements, the company aims to maximize its value and growth potential.
Most cancer patients die from metastatic disease, which is when the cancer travels to other parts of the body that ultimately cannot be treated, instead of the primary tumor. TapImmune's immunotherapies overcome the deficiencies of earlier cancer vaccine approaches by targeting both tumors and metastatic diseases. The company's approach further differentiates itself by influencing the body's own immune system to fight the disease.
Two clinical stage T-cell vaccine candidates are currently being advanced in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from the FDA Fast Track and Orphan Disease Designation. The U.S. market alone is very large for these cancers, with a combined 290,000 new patients estimated to be diagnosed each year. Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca are among the collaborators in these trials, and the U.S. Department of Defense has provided significant non-dilutive funding as well.
The company's off-the-shelf vaccines have been proven to boost patients' immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to treat a wide patient population across varied therapeutic areas of cancer. These vaccines have the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics.
PolyStart is TapImmune's unique DNA-based antigen expression system that helps the body recognize and kill target cells. It is a novel vaccine technology platform that creates a four-fold or greater increase in presentation of any antigen, which gives it unlimited application in oncology and infectious disease. The PolyStart platform further solidifies the company as a leader in the development of next-generation vaccines for cancer as it will be able to use this technology for its own vaccine candidates as well as generate additional value for the platform by licensing it to third parties.
The company plans to first build value through advancing candidates that treat women's cancers, while continuously developing its unique pipeline. As part of its long-term vision, the company is also developing proprietary technologies that can enhance the potency of DNA-based immunotherapies against other types of cancer and infectious disease. Other goals include discovering, acquiring and developing additional technologies that modulate antigen presentation and driving incremental value by monetizing proprietary protein expression systems through business partnerships. Disclaimer
TapImmune, Inc. Company Blog
TapImmune, Inc. News:
TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer
TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast
TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review
National Waste Management Holdings, Inc. (NWMH)
The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.1049, up 23.27%, on 45,376 volume with 7 trades. The stock’s average daily volume over the past 60 days is 23,041, and its 52-week low/high is $0.06/$0.51.
National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.
National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.
In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.
Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer
National Waste Management Holdings, Inc. Company Blog
National Waste Management Holdings, Inc. News:
National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC
National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling
National Waste Management Holdings, Inc. Ends Year on High Note, Announces Final Acquisition of 2016
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0008, up 14.29%, on 4,101,500 volume with 10 trades. The stock’s average daily volume over the past 60 days is 13,650,977 and its 52-week low/high is $0.0006/$0.028.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Continues Discussions with Madagascar for Energy Projects
Dominovas Energy Secures Gas Supply for South Africa
Dominovas Energy Dispatches Watkins to Meet With Gas Supplier
Players Network, Inc. (PNTV)
The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.028, up 7.69%, on 944,278 volume with 28 trades. The stock’s average daily volume over the past 60 days is 2,108,769, and its 52-week low/high is $0.0022/$0.048.
Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.
Green Leaf Farms Holdings, LLC (Green Leaf)
Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.
Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.
They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.
Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.
Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.
WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.
Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.
WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.
By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.
Marijuana and Media Strategy
While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer
Players Network, Inc. Company Blog
Players Network, Inc. News:
Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
Player's Network, Inc. Commences Trade on OTCQB
Player's Network Announces $350,000 Investment from CEO Mark Bradley
Today's Top 3
Wolf of Penny Stocks
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- ChineseInvestors.com, Inc. (CIIX) SeeThruEquity Issues Update on ChineseInvestors.com, Increasing Price Target to $3.75
- Dominovas Energy Corp. (DNRG) Enters Formal Negotiations to Open in India and Indonesia
- eXp World Holdings, Inc. (EXPI) to Present at Annual ROTH Conference
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- India Globalization Capital, Inc. (NYSE: IGC) IGC Announces Third Quarter Financial Results
- InMed Pharmaceuticals Inc. (IMLFF) InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry
- ProBility Media Corp. (PBYA) and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry
- Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
- Singlepoint, Inc. (SING) Greg Lambrecht, CEO of SinglePoint, Discusses Recent SING News and Industry Trends in A New Audio Interview withSmallCapVoice.com
- Stealth Technologies, Inc. (STTH) Announces 5 New Products
- TapImmune, Inc. (NASDAQ: TPIV) Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer